The head of the safety committee of the European Medicines Agency (EMA), Dr. Sabine Strauss, said that there is a possible relationship between the “Johnson & Johnson” vaccine and rare cases of blood clots.
She added that the cases registered with those who received the “AstraZeneca” and “Johnson & Johnson” vaccines have similarities, adding that “it is too early to draw conclusions” in this regard now.
The agency pointed out that all the rare cases of blood clots that were recorded after receiving the “Johnson & Johnson” vaccine were detected in the United States only, while the European Union did not record any of these rare cases.
Strauss reiterated that “the benefits of vaccines outweigh the risks.”
And the vaccination campaign against Covid-19 disease in Europe faced more turmoil after the American drug company “Johnson & Johnson” postponed the delivery of its vaccines, while Denmark said it would stop the use of the “AstraZeneca” vaccine due to its link to some cases of blood clots.
The delay in using the vaccine represents a new blow to the stalled vaccination campaign in Europe, which faced problems including poor coordination between local and regional authorities and a contractual dispute with “AstraZeneca”.